Clinical data
ATC code
  • None
  • ({[(2,3-Dihydroxy-7-nitro-5-quinoxalinyl)methyl]amino}methyl)phosphonic acid
CAS Number
PubChem CID
CompTox Dashboard (EPA)
Chemical and physical data
Molar mass330.193 g·mol−1
3D model (JSmol)
  • c1c(cc2c(c1CNCP(=O)(O)O)[nH]c(=O)c(=O)[nH]2)[N+](=O)[O-]
  • InChI=1S/C10H11N4O7P/c15-9-10(16)13-8-5(3-11-4-22(19,20)21)1-6(14(17)18)2-7(8)12-9/h1-2,11H,3-4H2,(H,12,15)(H,13,16)(H2,19,20,21)

Becampanel (INN) (code name AMP397) is a quinoxalinedione derivative drug which acts as a competitive antagonist of the AMPA receptor (IC50 = 11 nM).[1][2][3][4] It was investigated as an anticonvulsant for the treatment of epilepsy by Novartis, and was also looked at as a potential treatment for neuropathic pain and cerebral ischemia, but never completed clinical trials.[1][2][3][5]


  1. ^ a b John B. Taylor; D. J. Triggle (2007). Comprehensive medicinal chemistry II. Elsevier. p. 290. ISBN 978-0-08-044513-7.
  2. ^ a b Kwan P, Brodie MJ (September 2007). "Emerging drugs for epilepsy". Expert Opin Emerg Drugs. 12 (3): 407–22. doi:10.1517/14728214.12.3.407. PMID 17874969. S2CID 27627114.
  3. ^ a b Citraro R, Aiello R, Franco V, De Sarro G, Russo E (March 2014). "Targeting α-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate receptors in epilepsy". Expert Opin. Ther. Targets. 18 (3): 319–34. doi:10.1517/14728222.2014.874416. PMID 24387310. S2CID 1504490.
  4. ^ World Health Organization (1988). International Nonproprietary Names (INN) for Pharmaceutical Substances. W.H.O. ISBN 9789240560369.
  5. ^ Pathan SA, Jain GK, Akhter S, Vohora D, Ahmad FJ, Khar RK (September 2010). "Insights into the novel three 'D's of epilepsy treatment: drugs, delivery systems and devices". Drug Discov. Today. 15 (17–18): 717–32. doi:10.1016/j.drudis.2010.06.014. PMID 20603226.